NAD+ dosing: What studies and clinical protocols actually use

Search for NAD+ dosing and you will find numbers that disagree with each other by a factor of twenty. That is not because the sources are careless. It is because NAD+ is given in several different ways, and the form changes the number completely.

This article reviews what published studies and clinical protocols have actually used, organized by form. It is a review of the literature, not a set of instructions. Your provider determines your dose, and nothing here is a substitute for that.

What NAD+ is, and why form changes the dose

NAD+ is a coenzyme, not a peptide and not a hormone. It is a small molecule that NAD+-dependent enzymes require in order to work, and those enzymes are involved in DNA repair, cellular metabolism, and immune function [1].

The dosing problem comes from how the molecule moves. NAD+ is a pyridine nucleotide, and in that intact form it does not readily cross the intestinal wall or the cell membrane [2]. At higher concentrations outside the cell it gets broken down into smaller pieces, including NMN and nicotinamide riboside, which do have their own transporters and can enter cells directly [1].

This is why precursor compounds are used at all, and why an oral dose and an intravenous dose are not comparable numbers. They are not delivering the same thing to the same place by the same route.

Doses used in published studies, by form

Everything below is general information about what researchers and clinics have administered. It is not a recommendation, and your provider determines your dose.

Intravenous

The most commonly studied intravenous amount is 500 mg. A retrospective review of clients at a commercial wellness setting looked at four consecutive days of 500 mg NAD+ IV or 500 mg nicotinamide riboside IV, with 30 days of follow-up [1]. A separate randomized, placebo-controlled pilot study used a single acute dose of 500 mg by the intravenous route, with an oral 500 mg arm as a bridge comparison [3].

Infusion time is part of the dose in practice. NAD+ IV is typically run slowly, and how slowly is driven by tolerability rather than by the target amount.

Injection, intramuscular and subcutaneous

Injected amounts are much smaller than infused ones. A pilot trial series administered nicotinamide riboside at 50 mg or 100 mg intramuscularly or subcutaneously for three consecutive days, followed by a washout period [4]. A companion trial compared intramuscular, intravenous, and subcutaneous routes directly [4].

These are early studies with small numbers of participants. The evidence base for injected dosing is considerably thinner than for oral.

Oral precursors

Oral studies use precursors rather than NAD+ itself, and the dose range is wide. An eight-week randomized, double-blind, placebo-controlled trial gave 100, 300, or 1,000 mg of nicotinamide riboside daily and measured whole blood NAD+. The increases were dose-dependent: 22%, 51%, and 142% respectively, reached within two weeks and maintained through the study [5]. A separate pharmacokinetic study escalated from 250 mg twice daily to 1,000 mg twice daily over nine days [6].

A biomarker rising is not the same as a clinical outcome. These studies measured blood NAD+ levels, which is a measurement of the molecule, not a measurement of how anyone felt or functioned.

Nasal spray

This is where the honest answer is that published dosing data is sparse. Nasal delivery is used in clinical practice, but the peer-reviewed dosing literature for it is far behind the intravenous and oral routes. Anyone quoting a precise nasal protocol is working from practice patterns rather than from trial data, and it is worth asking where a specific number came from.

Why more is not automatically better

Two reasons, and both are practical.

Tolerability falls off. Reported adverse experiences with intravenous NAD+ include nausea, diarrhea, muscle cramping, chest discomfort, and dizziness [3]. These are strongly tied to infusion rate. Pushing more in faster is the reliable way to produce them.

The route matters more than the total. In a head-to-head comparison at the same 500 mg amount, nicotinamide riboside IV had a faster infusion time with better tolerability than NAD+ IV, and at three hours after infusion blood NAD+ was higher in the NR group [2]. Same number, different result. That is the clearest illustration available of why the amount on its own tells you very little.

There is also a plain gap in the evidence: systematic investigation of intravenous NAD+ safety and tolerability remains limited relative to how widely it is used [3].

Regulatory status, stated plainly

Compounded NAD+ preparations are not FDA-approved, and the FDA does not evaluate compounded drugs for safety, effectiveness, or quality.

The position on NAD+ specifically is unsettled rather than settled in either direction. The Pharmacy Compounding Advisory Committee recommended against including NAD+ on the relevant bulk substances list, and the FDA has proposed not listing it. Nobody should describe its compounding status as resolved.

This is worth knowing before you compare protocols, because a published clinical study and a commercial wellness protocol are not the same category of thing.

How dosing works in practice

Where a licensed provider is involved, dosing is not a fixed number you look up. It is a starting point that gets adjusted.

A provider reviews your health history and other medications, chooses a form and a starting amount, and then revisits it. In Luvo's program that review happens through a short re-questionnaire every four weeks, and a licensed provider adjusts the plan from there. The starting point is a provider's judgment about you, not a standard protocol.

On testing. Luvo does not run labs. If a provider you see wants bloodwork, that is arranged through your own provider or physician, not by Luvo.

Like anything prescribed, these preparations carry possible side effects, and a licensed provider is the person to review that with you.

Common questions

How often are NAD+ injections given?

Schedules in the published studies vary a lot and are usually short. The trials described above used three or four consecutive days followed by a washout [1, 4]. Ongoing maintenance schedules in clinical practice are not standardized. Your provider determines your schedule.

Can I take NAD+ every day?

Oral precursor studies have used daily dosing over eight weeks and longer [5]. Injected and infused routes in the published literature generally have not used continuous daily administration. Whether daily is appropriate for you is a question for a provider, not a general rule.

Do supplements and injections use the same doses?

No, and this is the single most common confusion. Oral studies have used up to 1,000 mg or more daily of a precursor [5], while injected studies have used 50 to 100 mg [4]. The numbers differ because absorption and route differ. Reading across between them is not meaningful.

What if I miss a dose?

There is no general answer, because it depends on the form and the schedule you are on. Ask the provider who set the schedule rather than doubling up on your own.

Next steps

If any of this sounds like what you are dealing with, the next step is a conversation with a licensed provider who can review your history and decide whether treatment makes sense for you. Nothing is prescribed or shipped without that review.

Explore Luvo's Longevity Program.